| A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (NCT05091619) | China National Biotec Group Company Limited | 2021-10-22 |
| Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . (NCT04099303) | CanSino Biologics Inc. | 2020-04-28 |
| To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years (NCT04618640) | Boryung Biopharma Co., Ltd. | 2019-12-26 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants (NCT04073459) | LG Chem | 2019-11-01 |
| Sero-epidemiological Survey of England in 2019/2020 - COVID-19 (NCT04061382) | University of Oxford | 2019-10-15 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults (NCT04238975) | Green Cross Corporation | 2019-10-14 |
| A Phase IV Study to Assess the Safety of EupentaTM Inj (NCT04056728) | LG Chem | 2019-09-23 |
| Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects (NCT04075175) | MassBiologics | 2019-04-23 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants (NCT03589768) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-24 |
| Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System (NCT03950986) | Atlanta VA Medical Center | 2018-10-15 |
| Evaluation of an Infant Immunization Encouragement Program in Nigeria (NCT03870061) | GiveWell | 2018-07-01 |
| The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks (NCT03931239) | Vabiotech | 2018-03-01 |
| Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan (NCT03341195) | Aga Khan University | 2018-01-01 |
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants (NCT03128489) | GlaxoSmithKline | 2017-12-01 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (NCT03208101) | LG Chem | 2017-07-03 |
| Safety Monitoring of Boostagen® Vaccine in Thailand (NCT07444502) | BioNet-Asia Co., Ltd. | 2017-06-30 |
| To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children (NCT04618939) | Boryung Biopharma Co., Ltd. | 2016-10-20 |
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02853929) | GlaxoSmithKline | 2016-09-19 |
| A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia (NCT02858440) | GlaxoSmithKline | 2016-09-13 |
| DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (NCT02817451) | Sanofi Pasteur, a Sanofi Company | 2016-07-14 |
| A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. (NCT02757950) | GlaxoSmithKline | 2016-07-14 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine (NCT02813486) | Green Cross Corporation | 2016-06-01 |
| Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda (NCT04177485) | Centers for Disease Control and Prevention | 2016-02-01 |
| Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02422264) | GlaxoSmithKline | 2016-01-22 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects (NCT02587520) | Sanofi Pasteur, a Sanofi Company | 2015-10-22 |
| Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (NCT02569879) | GlaxoSmithKline | 2015-10-01 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (NCT02428491) | Sanofi Pasteur, a Sanofi Company | 2015-04-20 |
| Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks (NCT02257645) | LG Life Sciences | 2015-03-01 |
| Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS (NCT02458183) | Boryung Pharmaceutical Co., Ltd | 2015-02-02 |
| Duration of Protection: GSK DTaP Vaccines (NCT02447978) | GlaxoSmithKline | 2015-02-01 |
| DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants (NCT02274285) | Sanofi Pasteur, a Sanofi Company | 2014-10-01 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants (NCT02096263) | GlaxoSmithKline | 2014-04-16 |
| Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents (NCT02118961) | Tanabe Pharma Corporation | 2014-04-01 |
| Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old (NCT02089347) | Sanofi Pasteur, a Sanofi Company | 2014-03-01 |
| DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (NCT02094833) | Sanofi Pasteur, a Sanofi Company | 2014-03-01 |
| Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children (NCT01988857) | GlaxoSmithKline | 2014-02-22 |
| Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. (NCT01993173) | Sanofi Pasteur, a Sanofi Company | 2013-11-01 |
| Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine (NCT03552445) | Korea University Guro Hospital | 2013-11-01 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (NCT01983540) | Sanofi Pasteur, a Sanofi Company | 2013-10-01 |
| Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya (NCT01878435) | Johns Hopkins Bloomberg School of Public Health | 2013-10-01 |
| A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (NCT01917357) | Crucell Holland BV | 2013-09-01 |
| Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China (NCT01933776) | Sanofi Pasteur, a Sanofi Company | 2013-08-01 |
| Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants (NCT01890850) | GlaxoSmithKline | 2013-07-01 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (NCT01738477) | GlaxoSmithKline | 2013-01-31 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (NCT01577732) | GlaxoSmithKline | 2012-12-08 |
| Diphtheria Vaccination in Adolescents With Inflammatory Bowel Disease (NCT03998215) | Medical University of Warsaw | 2012-12-01 |
| Tdap Vaccine in Post-Partum Women (NCT01711645) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-10-26 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents (NCT01689324) | Sanofi Pasteur, a Sanofi Company | 2012-09-01 |
| Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age (NCT01659996) | Sanofi Pasteur, a Sanofi Company | 2012-07-01 |
| Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents (NCT01629589) | Sanofi Pasteur, a Sanofi Company | 2012-06-01 |
| Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea (NCT01568060) | GlaxoSmithKline | 2012-05-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine (NCT01353703) | GlaxoSmithKline | 2012-04-16 |
| Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (NCT01546909) | Sanofi Pasteur, a Sanofi Company | 2012-02-01 |
| Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (NCT01491087) | Sanofi Pasteur, a Sanofi Company | 2011-12-01 |
| Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age (NCT01470287) | Novartis Vaccines | 2011-12-01 |
| Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose (NCT01439165) | Sanofi Pasteur, a Sanofi Company | 2011-11-01 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01453998) | GlaxoSmithKline | 2011-10-14 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (NCT01449812) | GlaxoSmithKline | 2011-10-01 |
| Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (NCT01444781) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents (NCT01362322) | GlaxoSmithKline | 2011-07-01 |
| Regulatory Post-Marketing Surveillance Study for TETRAXIM™ (NCT01437423) | Sanofi Pasteur, a Sanofi Company | 2011-06-01 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (NCT01358825) | GlaxoSmithKline | 2011-05-30 |
| Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination (NCT01357720) | Crucell Holland BV | 2011-05-01 |
| Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults (NCT01323959) | GlaxoSmithKline | 2011-04-01 |
| Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age (NCT01346293) | Sanofi Pasteur, a Sanofi Company | 2011-04-01 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (NCT01309646) | GlaxoSmithKline | 2011-03-04 |
| Study of Adacel® Vaccine Administered to Persons 10 Years of Age (NCT01311557) | Sanofi | 2011-03-01 |
| Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older (NCT01287949) | Sanofi Pasteur, a Sanofi Company | 2011-01-01 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01248884) | GlaxoSmithKline | 2010-12-09 |
| Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (NCT01214889) | Sanofi | 2010-09-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (NCT01171989) | GlaxoSmithKline | 2010-08-18 |
| A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants (NCT01177722) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| Evaluation of Boostrix™10 Years After Previous Booster Vaccination (NCT01147900) | GlaxoSmithKline | 2010-06-15 |
| Post Marketing Surveillance for ADACEL™ in South Korea (NCT01137435) | Sanofi Pasteur, a Sanofi Company | 2010-06-01 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (NCT01090453) | GlaxoSmithKline | 2010-05-17 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers (NCT01106092) | GlaxoSmithKline | 2010-05-13 |
| Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B (NCT01362517) | Crucell Holland BV | 2010-04-01 |
| Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (NCT01105559) | Sanofi | 2010-04-01 |
| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine (NCT01086423) | GlaxoSmithKline | 2010-03-01 |
| A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants (NCT01062477) | Sanofi | 2010-01-01 |
| A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) (NCT01003431) | Merck Sharp & Dohme LLC | 2009-12-01 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) (NCT00964028) | GlaxoSmithKline | 2009-12-01 |
| A Study to Assess the Safety of Adacel® Vaccine (NCT01040052) | Sanofi Pasteur, a Sanofi Company | 2009-12-01 |
| Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age (NCT01031303) | Sanofi | 2009-12-01 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (NCT00970307) | GlaxoSmithKline | 2009-08-13 |
| Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (NCT00871000) | GlaxoSmithKline | 2009-04-01 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. (NCT00871741) | GlaxoSmithKline | 2009-04-01 |
| An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster (NCT00870350) | Swedish Institute for Infectious Disease Control | 2009-04-01 |
| Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years (NCT00871117) | GlaxoSmithKline | 2009-03-31 |
| Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. (NCT00835237) | GlaxoSmithKline | 2009-02-17 |
| Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease (NCT00855855) | Sanofi Pasteur, a Sanofi Company | 2009-02-01 |
| Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine (NCT00877357) | Shantha Biotechnics Limited | 2009-01-01 |
| Pertussis Vaccine in Healthy Pregnant Women (NCT00707148) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-01-01 |
| Immunogenicity and Safety of Adacel Polio Vaccine (NCT00797511) | Sanofi | 2008-11-01 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants (NCT00753649) | GlaxoSmithKline | 2008-09-23 |
| Database Surveillance Safety Study of PENTACEL® Vaccine (NCT00804284) | Sanofi Pasteur, a Sanofi Company | 2008-09-01 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children (NCT00696423) | GlaxoSmithKline | 2008-06-07 |
| Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose (NCT00712959) | Sanofi Pasteur, a Sanofi Company | 2008-06-01 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants (NCT00831753) | Sanofi Pasteur, a Sanofi Company | 2008-05-01 |
| Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (NCT00654901) | Sanofi Pasteur, a Sanofi Company | 2008-03-01 |